Genomic Health and Pfizer Collaborate on Renal Cell Carcinoma
Posted on: Tuesday, 8 January 2008, 09:01 CST
Genomic Health has entered into collaboration with Pfizer on the development of a genomic test to estimate the risk of recurrence following surgery for patients with Stage I-III renal carcinoma, clear cell type, which has not spread to other parts of the body.
As part of the collaboration, the companies will apply the same molecular technology and clinical strategy Genomic Health used to develop its Oncotype DX breast cancer test.
Chu Chang, vice president of business development at Genomic Health, said: "This collaboration further expands our efforts to develop genomic tests for a variety of cancers that allow physicians and patients to individualize treatment decisions."
Source: Datamonitor
Related Articles
- Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canada's Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
- MEDecision Announces Webinar to Unveil New Alineo(TM) Collaborative Health Care Management Platform
- MEDecision Introduces Alineo(TM) Collaborative Health Care Management Solution
- MEDecision Outlines 2008 Initiative to Provide Simplified, Smart and State-of-the-Art Collaborative Health Care Management
- MEDecision Announces General Availability of New Collaborative Health Care Management Application
- BioServe Acquires Genomics Collaborative
- MEDecision Aims to Drive Adoption of Health Information Exchange With New Center for Collaborative Health
- Accenture and SAP Partner for Collaborative Health Network
- Celera Genomics' Collaborators Present Feasibility Data on Fragile X Research Assay at ACMG Meeting in San Diego, CA
- Affymetrix and Vita Genomics Collaborate to Develop Microarray-Based IVD Products
 |
 |
User Comments (0)
RSS Feeds